



Press release
August 22, 2008

AnaMar strengthens financial position

LinkMed's portfolio company AnaMar Medical is strengthening its financial position through a directed share issue worth SEK 20 million. The two principal owners LinkMed and Koncentra Holding are each investing SEK 10 million in the issue.

AnaMar Medical is strengthening its financial position through a directed share issue prior to carrying out a first round of clinical trials on humans (Phase 1) with MCR (AM240) to combat chronic joint disease. The trials are planned for the second half of 2008. AnaMar Medical's principal shareholders Koncentra Holding and LinkMed are participating in the issue on equal terms with an investment of SEK 10 million each.

LinkMed's ownership stake in AnaMar Medical is 24.9% percent.

About AnaMar Medical

AnaMar Medical develops drugs and biomarkers for diagnosing and monitoring/predicting chronic joint diseases such as rheumatoid arthritis and chronic joint inflammation. AnaMar Medical has five drug candidates in preclinical trials, two biomarkers in prototype development and two commercially available biomarkers, COMP®-Elisa and Animal COMP-Elisa.

For more information contact:

LinkMed CEO, Ingemar Lagerlöf, tel. +46 8 508 939 93

LinkMed, in collaboration with innovators, develops life science companies. By contributing entrepreneurship and capital, LinkMed has created a portfolio of twelve companies, seven in biotechnology and five in medical technology. The company's principal owners are FastPartner, Koncentra Holding, and the founder Ingemar Lagerlöf. The LinkMed share is listed on the OMX Nordic Exchange Stockholm in the small-cap sector (ticker:LMED).